



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)




PRODUCT INFORMATION



Oxaprozin-d₅ Item No. 33279

Formal Name: 4-phenyl-5-(phenyl-d₅)-2-oxazolepropanoic acid
MF: C₁₈H₁₀D₅NO₃
FW: 298.4
Chemical Purity: ≥98% (Oxaprozin)
Deuterium Incorporation: ≥99% deuterated forms (d₁-d₅); ≤1% d₀
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Oxaprozin-d₅ is intended for use as an internal standard for the quantification of oxaprozin (Item No. 15476) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Oxaprozin-d₅ is supplied as a solid. A stock solution may be made by dissolving the oxaprozin-d₅ in the solvent of choice, which should be purged with an inert gas. Oxaprozin-d₅ is soluble in organic solvents such as ethanol, methanol, DMSO, and dimethyl formamide.

Description

Oxaprozin is a non-steroidal anti-inflammatory drug (NSAID) and COX inhibitor (IC₅₀s = 2.2 and 36 μM for human COX-1 and COX-2, respectively).¹ It decreases acetic acid-induced writhing times and carrageenan-induced paw edema in mice when administered at doses of 100 and 70 mg/kg, respectively.² Formulations containing oxaprozin have been used in the treatment of pain associated with osteoarthritis and rheumatoid arthritis.

References

1. Kawai, S., Nishida, S., Kato, M., *et al.* Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. *Eur. J. Pharmacol.* **347(1)**, 87-94 (1998).
2. Zhou, X.P., Zhang, M.X., Sun, W., *et al.* Design, synthesis, and *in-vivo* evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug. *Biol. Pharm. Bull.* **32(12)**, 1986-1990 (2009).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/03/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM